Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
Enterprise Analytics, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
Transplant Proc. 2021 May;53(4):1227-1236. doi: 10.1016/j.transproceed.2021.02.014. Epub 2021 Feb 25.
Solid organ transplant (SOT) recipients are a complex, immunocompromised population in whom greater coronavirus disease 2019 (COVID-19) mortality has been reported compared with the general population.
We examined a retrospective cohort of 58 SOT recipients with first-wave COVID-19, comparing patients with severe and nonsevere illness. Additionally, SOT recipients are compared with general patients with first-wave COVID-19.
Organs transplanted included 38 kidneys, 8 livers, 5 hearts, and 3 pancreases. Average SOT recipient age was 57.4 years; 62% were male; 46.6% were African American 36.2% were white. Comorbidities included hypertension (86%), chronic kidney disease (86%), diabetes mellitus (50%), coronary artery disease (26%), and chronic obstructive pulmonary disease (14%). Twenty patients had severe COVID-19 (34.5%) and 38 had nonsevere disease (65.5%). Severe disease was more common in older SOT recipients with comorbidities and was associated with cough, dyspnea, pneumonia, C-reactive protein >10 mg/L, and platelet count <150/μL. Sex, race, body mass index, time from transplant, baseline immunosuppression, and diagnosis month did not differ among those with severe and nonsevere COVID-19. Seventy percent of SOT recipients were hospitalized vs 27.2% of general patients with COVID-19 and inpatient SOT recipients had a higher mechanical ventilation rate. Though a trend toward longer length of stay, higher intensive care unit admission, and greater inpatient mortality was observed (19.5% vs 14.8%), these differences were not significant.
The severe acute respiratory syndrome coronavirus 2 has greatly impacted SOT recipients. One-third of our SOT recipients seen during the first wave had severe illness with associated standard risk factors for poor outcome. Compared with general first-wave patients, more SOT recipients were hospitalized, although inpatient COVID-19 mortality did not significantly differ.
实体器官移植(SOT)受者是一个复杂的免疫功能低下人群,与普通人群相比,COVID-19 死亡率更高。
我们研究了 58 例首例 COVID-19 的 SOT 受者的回顾性队列,比较了重症和非重症患者。此外,还将 SOT 受者与首例 COVID-19 的普通患者进行了比较。
移植的器官包括 38 个肾脏、8 个肝脏、5 个心脏和 3 个胰腺。SOT 受者平均年龄为 57.4 岁;62%为男性;46.6%为非裔美国人,36.2%为白人。合并症包括高血压(86%)、慢性肾脏病(86%)、糖尿病(50%)、冠状动脉疾病(26%)和慢性阻塞性肺疾病(14%)。20 例患者患有严重 COVID-19(34.5%),38 例患者患有非严重疾病(65.5%)。患有严重疾病的 SOT 受者年龄较大,合并症较多,伴有咳嗽、呼吸困难、肺炎、C 反应蛋白>10mg/L 和血小板计数<150/μL。严重和非严重 COVID-19 患者之间的性别、种族、体重指数、移植后时间、基础免疫抑制和诊断月份无差异。70%的 SOT 受者住院,而 COVID-19 普通患者住院率为 27.2%,住院 SOT 受者的机械通气率更高。尽管观察到住院时间延长、重症监护病房入住率升高和住院死亡率增加的趋势(19.5%比 14.8%),但这些差异无统计学意义。
严重急性呼吸综合征冠状病毒 2 对 SOT 受者影响很大。我们观察到首例 COVID-19 期间,三分之一的 SOT 受者病情严重,预后不良的相关标准危险因素存在。与普通首例患者相比,更多的 SOT 受者住院,但住院 COVID-19 死亡率无显著差异。